Released May 11, 2020, after the close
10-Q filed May 11, 2020, 41 days after period end · 0001564590-20-024213
Q1 2020 · 10-Q
Revenue$2.52M$2.52M −4.4% vs Q1 2019−10.2% vs Q4 2019
Net Income-$33.52M-$33.52M N/M vs Q1 2019N/M vs Q4 2019
EPS Diluted-$0.44-$0.44 N/M vs Q1 2019N/M vs Q4 2019
Operating Income-$34,492,000N/M
Operating Cash Flow-$26,673,000N/M
Free Cash Flowderived-$27,743,000N/M
Margins · derived
Operating margin-1371.5%−594.6 pt vs Q1 2019
Net margin-1332.8%−582.0 pt vs Q1 2019
What the release said
The release
Same quarter
| Metric | Q1 2020 | Q1 2019 | Q1 2018 | Q1 2017 |
|---|---|---|---|---|
| Revenue | $2.52M | $2.63M | $1.03M | $1.03M |
| Net Income | -$33.52M | -$19.76M | -$14.14M | -$10.13M |
| EPS Diluted | -$0.44 | -$0.30 | -$0.27 | -$0.24 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR